On May 21, 2026, BioCardia, Inc. announced positive preliminary results from the CardiAMP Cell Therapy trial at a conference in Paris, showing increased exercise tolerance by an average of 179 seconds and an 82% reduction in angina episodes six months after treatment. The procedure was well tolerated, with no major adverse events reported.